Saint John's Health Center

A phase 4, open-label efficacy and safety study of methotrexate and monthly pegloticase co-administration in patients with uncontrolled gout

Abstract Background Pegloticase is an infused pegylated uricase enzyme indicated for the treatment of uncontrolled gout in adults who did not respond to or cannot tolerate oral urate-lowering therapies; pegloticase is administered as 8-mg infusions every 2 weeks (Q2W). However, f...